WOCKPHARMA2024-10-012024-12-31 WOCKPHARMA2024-10-012024-12-31 WOCKPHARMA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member WOCKPHARMA2024-12-31 WOCKPHARMA2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532300 WOCKPHARMA NA Wockhardt Limited Equity 2024-04-01 2025-03-31 2025-02-07 2025-02-03 INR Crores Third quarter 11:45:00 13:25:00 2025-02-07 2025-02-07 Not applicable Single segment Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Consolidated 7210000000.00 80000000.00 7290000000.00 1210000000.00 1220000000.00 190000000.00 1640000000.00 600000000.00 550000000.00 1670000000.00 7080000000.00 210000000.00 0.00 210000000.00 10000000.00 0.00 10000000.00 0.00 200000000.00 0.00 0.00 0.00 0.00 200000000.00 -700000000.00 -500000000.00 140000000.00 60000000.00 -380000000.00 -120000000.00 810000000.00 5 0.91 0.91 0.00 0.00 0.91 0.91 0.00 0.00 0.00 1. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 07, 2025. The results have been subjected to limited review by the Statutory Auditors of the Company. 2. The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute ‘the Group’) and are prepared by applying Ind AS 110 - Consolidated Financial Statements . 3.Key Financials on Standalone basis: Particulars 3months ended 3 months ended 3months ended 9months ended 9months ended Year ended 31/12/2024 30/09/2024 31/12/2023 31/12/2024 31/12/2023 31/03/2024 Total Income 331 381 293 1088 816 1195 Profit/(Loss) (22) (36) (74) (52) (296) (422) before Tax Profit/(Loss) (22) (36) (74) (52) (296) (422) after tax Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com ) and also on the Company's website www.wockhardt.com. 4. During the quarter ended December 31, 2024, the Company has alloted 13,000 (year to date 21,610) equity shares of Face value of Rs. 5 each pursuant to exercise of Employee Stock option. 5. Further to the approval of the Board of Directors and Shareholders at their meetings , the Company has, on November 11, 2024, alloted 9,049,773 Equity Shares of Rs. 5/- each to successful Qualified Institutional Buyers at the issue price of Rs.1,105/- per share, aggregating to approximately Rs. 1,000 crore 6. The Group is exclusively into Pharmaceutical business segment. 7. For List of Subsidiaries as on December 31, 2024 please refer Annexure. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 22690000000.00 470000000.00 23160000000.00 4530000000.00 4250000000.00 -60000000.00 4850000000.00 2060000000.00 1640000000.00 5830000000.00 23100000000.00 60000000.00 0.00 60000000.00 60000000.00 120000000.00 180000000.00 0.00 -120000000.00 0.00 0.00 0.00 0.00 -120000000.00 150000000.00 30000000.00 -220000000.00 100000000.00 20000000.00 10000000.00 810000000.00 5 -1.41 -1.41 0.00 0.00 -1.41 -1.41 0.00 0.00 0.00 Exchange fluctuation loss, net -320000000.00 Other Expense 1990000000.00 Exchange fluctuation loss, net -110000000.00 Other Expense 5940000000.00 tems that will not be reclassified to Profit or Loss - (charge)/ credit (consisting of re-measurement of net defined benefit (liability) / asset) -10000000.00 tems that will not be reclassified to Profit or Loss - (charge)/ credit (consisting of re-measurement of net defined benefit (liability) / asset) -10000000.00 -10000000.00 -10000000.00 0.00 0.00 Items that will be reclassified to Profit or Loss - (charge)/ credit (Consisting of Exchange differences on translating the financial statements of foreign operations) -690000000.00 Items that will be reclassified to Profit or Loss - (charge)/ credit (Consisting of Exchange differences on translating the financial statements of foreign operations) 160000000.00 -690000000.00 160000000.00 0.00 0.00